At a glance
| Known as | E2086 |
|---|---|
| Sponsor | Eisai |
| Mechanism | Oral orexin receptor agonist |
| Stage | Phase 2 |
| Indications | NT1 |
| Registered trials | 5 · 2 recruiting |
| Last verified | 4 Aug 2026 |
Where it stands
E2086 is Eisai's entry in the orexin agonist class and the least-covered of the mid-stage programmes. It advanced to Phase 2 with study NCT07493265, now recruiting, which evaluates efficacy and safety in adults with narcolepsy.
It got there off a Phase 1 package that included a placebo- and active-comparator-controlled study in narcolepsy type 1. Running an active comparator that early is a stronger design than the placebo-only studies typical at Phase 1, because it puts the compound against an existing treatment rather than against nothing.
Registered trials
All 5 studies on ClinicalTrials.gov that name E2086 or its development code, pulled from the registry on 4 Aug 2026.
| Registry ID | Study | Phase | Status | Primary completion |
|---|---|---|---|---|
NCT07493265 |
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With NarcolepsyEfficacy and safety in adults with narcolepsy. Recruiting.64 participants | Phase 2 | Recruiting | 14 Feb 2027 |
NCT07308236 |
A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants10 participants | Phase 1 | Recruiting | 23 Feb 2026 |
NCT06481488 |
A Study of E2086 in Healthy Adult Participants32 participants | Phase 1 | Completed | 13 Dec 2024 |
NCT06462404 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of E2086 Compared to Placebo and Active Comparator in Adult Participants With Narcolepsy Type 122 participants | Phase 1 | Completed | 17 Mar 2025 |
NCT05745207 |
A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants53 participants | Phase 1 | Completed | 18 Jan 2024 |
Trial records are maintained by the sponsor and change without notice. Follow each link for current recruitment status and eligibility.
E2086 — common questions
What phase is E2086 in?
Phase 2. Study NCT07493265 is recruiting and evaluates efficacy and safety in adults with narcolepsy. It followed completed Phase 1 studies, including a placebo- and active-comparator-controlled study in narcolepsy type 1.
Who makes E2086?
Eisai, the Japanese pharmaceutical company.
The rest of the class
Compounds sharing at least one indication with E2086 come first.
oveporexton
Takeda Pharmaceutical Company · Approved · NT1
alixorexton
Alkermes plc · Phase 3 · NT1 / NT2 / IH
cleminorexton
Centessa Pharmaceuticals · Phase 3 · NT1 / NT2 / IH
TAK-360
Takeda Pharmaceutical Company · Phase 2 · NT1 / NT2 / IH
ALKS 4510
Alkermes plc · Phase 1 · Fatigue in MS / Fatigue in Parkinson's
ALKS 7290
Alkermes plc · Phase 1 · ADHD
BP-205
Harmony Biosciences Holdings · Phase 1 · Not yet specified
ORX142
Centessa Pharmaceuticals · Phase 1 · Neurological / Neurodegenerative
ORX489
Centessa Pharmaceuticals · Phase 1 · Neuropsychiatric
Source
This entry was last checked against its primary source on 4 Aug 2026 by Simon Stawski: https://clinicaltrials.gov/study/NCT07493265
Found something out of date? Send a correction with a primary source and it will be fixed.
Get told when this changes
One email when E2086 changes phase, reads out, or hits a regulatory milestone.
One email per real change. No tracking pixels, no list rental, one-click unsubscribe.